Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice

Ítems similars

• A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses
  per: Katz-Levy, Yael, et al.
  Publicat: (1997)
• The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes
  per: Paas-Rozner, Miri, et al.
  Publicat: (2001)
• A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4(+) T cells
  per: Paas-Rozner, Miri, et al.
  Publicat: (2003)
• Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes
  per: Faber-Elmann, Anat, et al.
  Publicat: (1998)
• Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis.
  per: Zisman, E, et al.
  Publicat: (1996)